Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome

Inflammatory manifestations (IM) are well described in adult patients with myelodysplastic syndrome (MDS), but the presentation is highly variable and no standardized treatment exists. This phenomenon is rarely reported in children. As more pediatric patients are hematopoietic stem cell transplantation (HSCT) candidates, the role of anti‐inflammatory treatment in relation to HSCT should be defined.

[1]  S. Miyano,et al.  Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia , 2021, Haematologica.

[2]  S. Izraeli,et al.  Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias , 2020, British journal of haematology.

[3]  J. Mullikin,et al.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.

[4]  H. Kantarjian,et al.  The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia , 2020, Leukemia.

[5]  G. Garcia-Manero,et al.  Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs , 2020, Nature Immunology.

[6]  K. Ono,et al.  The acquisition of trisomy 8 associated with Behçet's-like disease in myelodysplastic syndrome , 2020, Leukemia research reports.

[7]  Y. Erzin,et al.  How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review , 2020, Annals of Hematology.

[8]  F. Rieux-Laucat,et al.  After 95 years, it's time to eRASe JMML. , 2020, Blood reviews.

[9]  Supat Thongjuea,et al.  Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia , 2019, bioRxiv.

[10]  A. List,et al.  The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. , 2019, Blood.

[11]  M. Raaijmakers,et al.  The mesenchymal niche in MDS. , 2019, Blood.

[12]  A. Shimamura,et al.  Genetic predisposition to MDS: clinical features and clonal evolution. , 2019, Blood.

[13]  F. Carrat,et al.  Gastrointestinal Behcet’s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review , 2018, Leukemia & lymphoma.

[14]  F. Carrat,et al.  Inflammatory disorders associated with trisomy 8‐myelodysplastic syndromes: French retrospective case‐control study , 2018, European journal of haematology.

[15]  P. Fenaux,et al.  Autoimmune manifestations associated with myelodysplastic syndromes , 2018, Annals of Hematology.

[16]  M. Wlodarski,et al.  Monosomy 7 in Pediatric Myelodysplastic Syndromes. , 2018, Hematology/oncology clinics of North America.

[17]  H. Tamary,et al.  Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias , 2018, European journal of haematology.

[18]  F. Locatelli,et al.  How I treat myelodysplastic syndromes of childhood. , 2018, Blood.

[19]  J. Piette,et al.  Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. , 2017, Autoimmunity reviews.

[20]  C. Mecucci,et al.  Practical considerations for diagnosis and management of patients and carriers. , 2017, Seminars in hematology.

[21]  M. Wlodarski,et al.  Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants , 2017, Leukemia.

[22]  H. Tsukahara,et al.  Pediatric intestinal Behçet disease complicated by myeloid malignancies , 2017, International Journal of Hematology.

[23]  J. Klco,et al.  The genomic landscape of pediatric myelodysplastic syndromes , 2016, Nature Communications.

[24]  R. Stone,et al.  Autoimmunity and Inflammation in Myelodysplastic Syndromes , 2016, Acta Haematologica.

[25]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[26]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[27]  B. Williamson,et al.  Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome , 2016, Hematology reports.

[28]  O. Ohara,et al.  Autoimmunity Including Intestinal Behçet Disease Bearing the KRAS Mutation in Lymphocytes: A Case Report , 2016, Pediatrics.

[29]  J. Piette,et al.  Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.

[30]  Sheng Wei,et al.  The inflammatory microenvironment in MDS , 2015, Cellular and Molecular Life Sciences.

[31]  S. Scholl,et al.  Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review , 2014, European journal of haematology.

[32]  D. Inokuma,et al.  Behçet's disease-like symptoms associated with myelodysplastic syndrome with trisomy 8: a case report and review of the literature. , 2014, Acta dermato-venereologica.

[33]  C. Kim,et al.  Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies , 2012, American journal of medical genetics. Part A.

[34]  C. Niemeyer,et al.  Advances in the prognostication and management of advanced MDS in children , 2011, British journal of haematology.

[35]  J. B. Oliveira,et al.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. , 2011, Blood.

[36]  T. Morio,et al.  Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. , 2011, Blood.

[37]  J. Harbott,et al.  Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. , 2010, Blood.

[38]  A. Green,et al.  Constitutional trisomy 8 and Behçet syndrome , 2009, American journal of medical genetics. Part A.

[39]  Rainer Haas,et al.  Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes , 2008, Annals of Hematology.

[40]  R. Moots,et al.  Myelodysplastic syndrome with trisomy 8 associated with Behçet syndrome: An immunologic link to a karyotypic abnormality , 2008, Pediatric blood & cancer.

[41]  V. Tonk,et al.  Juvenile myelomonocytic leukemia in a child with Crohn disease. , 2006, Cancer genetics and cytogenetics.

[42]  N. Hatta,et al.  BehÇet’s disease associated with myelodysplastic syndrome with elevated levels of inflammatory cytokines , 2003, Modern rheumatology.

[43]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[44]  J. Maciejewski,et al.  Application of the Molecular Analysis of the T-Cell Receptor Repertoire in the Study of Immune-Mediated Hematologic Diseases , 2003, Hematology.

[45]  I. Baumann,et al.  A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases , 2003, Leukemia.

[46]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[47]  K. Koike,et al.  Lupus nephritis in juvenile myelomonocytic leukemia. , 1999, Clinical nephrology.

[48]  A Orfao,et al.  Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS , 2014, Leukemia.

[49]  S. Bicciato,et al.  PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy , 2010, Leukemia.

[50]  S. Nagataki,et al.  Behçet's disease complicated with myelodysplastic syndrome a report of two cases and review of the literature , 2005, Clinical Rheumatology.

[51]  A. Brice,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2002, Nature Genetics.